

First revision

Stimulating brain recovery after stroke using theranostic albumin nanocarriers loaded with nerve growth factor in combination therapy

Tivadar Feczkó^{1,2,3}, Albrecht Piiper¹, Saema Ansar⁴, Frank W Blixt⁴, Mukul Ashtikar⁵, Susanne Schiffmann⁵, Thomas Ulshöfer⁵, Michael J. Parnham⁵, Yifat Harel⁶, Liron Limor Israel⁶, Jean-Paul Lellouche⁶, Matthias G. Wacker^{5,7*}

- 1: Department of Medicine 1, University Hospital Frankfurt, Frankfurt, Germany
- 2: Institute of Materials and Environmental Chemistry, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary
- 3: Research Institute of Biomolecular and Chemical Engineering, University of Pannonia, Veszprém, Hungary
- 4: Department of Clinical Sciences, Lund University, Lund, Sweden
- 5: Fraunhofer Institute for Molecular Biology and Applied Ecology, Translational Medicine and Pharmacology, Frankfurt/Main
- 6: Department of Chemistry, Bar Ilan University, Israel
- 7: Institute of Pharmaceutical Technology, Goethe University, Frankfurt/Main

*Corresponding author

Dr. Matthias G. Wacker

Pharmaceutical Technology and Nanosciences

Fraunhofer-Institute for Molecular Biology and Applied Ecology (IME)

Translational Medicine and Pharmacology (TMP)

Building N230, Room 2.03

Max-von-Laue-Straße 9, D-60438 Frankfurt/Main

Phone +49 69 798 - 296 91

Fax +49 69 798 - 296 94

www.ime.fraunhofer.de

Abstract

For many years, delivering drug molecules across the blood brain barrier has been a major challenge. The neuropeptide nerve growth factor is involved in the regulation of growth and differentiation of cholinergic neurons and holds great potential in the treatment of stroke. However, as with many other compounds, the biomolecule is not able to enter the central nervous system. In the present study, nerve growth factor and ultra-small particles of iron oxide were co-encapsulated into a chemically crosslinked albumin nanocarrier matrix which was modified on the surface with apolipoprotein E. These biodegradable nanoparticles with a size of 212 ± 1 nm exhibited monodisperse size distribution and low toxicity. They delivered NGF through an artificial blood brain barrier and were able to induce neurite outgrowth in PC12 cells *in vitro*. In an animal model of stroke, the infarct size was significantly reduced compared to the vehicle control. The combination therapy of NGF and the small-molecular MEK inhibitor U0126 showed a slight but not significant difference compared to U0126 alone. However, further *in vivo* evidence suggests the hypothesis that successful delivery of the neuropeptide is possible as well as the synergism between those two treatments.

Keywords:

BBB, brain, nanoparticles, drug delivery, theranostic, NGF, MEK

Abbreviations

ApoE3	Apolipoprotein E3
BBB	blood brain barrier
CAN	cerium ammonium nitrate
DCM	dichloromethane
DMSO	dimethyl sulfoxide
EDC	1-ethyl-3(3-dimethylaminopropyl) carbodiimide
ERK	Extracellular signal-regulated kinase
HSA	human serum albumin
MALHEX-NH-PEG-NHS	Maleinimido hexanoic- ω -NHS PEG
MEK	mitogen-activated protein kinase kinase
mPEG-SPA-5000	Succinimidyl propionic acid PEG NHS
MRI	magnetic resonance imaging
NGF	nerve growth factor
NHS	N- hydroxysuccinimide
PAR	passive avoidance reflex
PBCA	poly(butyl cyanoacrylate)
PBS	phosphate buffered saline
PDI	polydispersity index
PEG	polyethylene glycol
PVA	polyvinyl alcohol
SEM	scanning electron microscope
TEM	transmission electron microscopy
USPIO	ultra-small superparamagnetic iron oxide

1. Introduction

As one of the most important neuropeptides, nerve growth factor (NGF) is involved in the regulation of growth and differentiation of cholinergic neurons [1]. Further, it plays a major role in cell survival after ischemic stroke which is a leading cause of death globally [2]. A significant reduction of delayed neuronal death was observed after the administration of NGF into the cerebral ventricle of rats [3] and even some early clinical evidence highlights a beneficial effect on recovery of hypoxic-ischemic brain injuries and cerebral perfusion [4, 5].

Despite the great potential in the treatment of stroke, NGF is not able to pass the blood-brain barrier (BBB) which makes clinical administration dependent on invasive neurosurgical procedures [6, 7]. The BBB is created by the cerebral endothelial cells forming tight junctions and sealing the paracellular pathway into the brain [8]. As a consequence, the composition of the extracellular fluid within the central nervous system (CNS) can be precisely controlled [8]. The endothelial tissue exhibits polarized expression of transport proteins [8]. Some of these transporters were addressed using nanocarrier systems modified on their surface with targeting moieties such as transferrin [9], insulin [10] or the apolipoproteins (Apo) E and A-1 [11, 12]. Poly(butyl cyanoacrylate) (PBCA) nanoparticles coated with polysorbate 80 effectively delivered NGF to the CNS in an animal model of Alzheimer's disease [13].

This coating leads to an adsorption of Apo A-1, B, and E [14]. Kreuter and co-workers confirmed an active endocytotic uptake mechanism of ApoE-conjugated albumin nanoparticles *in vitro* [15] and *in vivo* [12]. In this context, the low density lipoprotein receptor (LRP1) was held responsible for the uptake [15]. Human serum albumin (HSA) is the most abundant blood protein and has been used as a carrier material for a number of therapeutic agents such as survivin miRNA plasmid [16], polo-like kinase [17], doxorubicin [18, 19] or paclitaxel [20].

Exploring the biodistribution of nanocarriers is an important requirement for clinical translation of nanocarrier delivery. In this context, ultra-small superparamagnetic particles of iron oxide (USPIO) were encapsulated into HSA nanoparticles serving as contrast agents for magnetic resonance (MR) imaging [21, 22]. A novel species of

maghemite core particles was used [23-25]. The resulting diagnostic HSA nanocarriers were successfully tested *in vivo* [21].

In the present study, advanced theranostic nanocarriers for the treatment of stroke were synthesized by co-desolvation of NGF and HSA in the presence of cerium ammonium nitrate (CAN)-stabilized USPIO. The surface of resulting nanocarriers was functionalized using apolipoprotein E to facilitate an active transport into the brain. After a detailed physicochemical characterization, the nanocomposites were evaluated *in vitro* and *in vivo*. Biocompatibility of the nanocarriers as well as the bioactivity of NGF were confirmed in rat pheochromocytoma (PC12) cells. The nanoparticles effectively induced neurite outgrowth without exhibiting significant cytotoxicity. Drug release was investigated using the dispersion releaser technology [26, 27]. The transport of NGF into the brain was confirmed *in vitro* in bEnd3 cells. Finally, a combination of the nanocarriers with the small-molecular mitogen-activated protein kinase (MEK) inhibitor U0126 was tested in an *in vivo* model of stroke. U0126 protects the brain against ischemic brain damage and a synergistic effect was assumed [28, 29].

2. Materials and methods

2.1. Materials

HSA, glutaraldehyde 25% aqueous solution, D-trehalose, saccharose, and mannitol were obtained from Sigma Aldrich (Munich, Germany). Nerve growth factor was supplied by Alomone Labs (Jerusalem, Israel). Apolipoprotein E3 was purchased from Peprotech (Hamburg, Germany). ATTO647N was purchased from ATTO-TEC GmbH (Siegen, Germany). 2-Iminoethanol HCL (Traut's reagent) was obtained from Thermo Scientific (USA). Succinimidyl propionic acid PEG NHS (mPEG-SPA-5000) was given by NANOCS (USA). α -Maleimidohexanoic- ω -NHS PEG (MALHEX-NH-PEG-NHS) was manufactured by RAPP Polymere (Tübingen, Germany). Trypsinogen and proteinase K for the release experiments was purchased from Sigma Aldrich (Darmstadt, Germany).

2.2. Synthesis of Ce^{3/4+}-cation-doped maghemite iron oxide particles

The USPIO were synthesized using a nanofabrication method described previously [23]. In brief, FeCl₃ • 6H₂O (Fe³⁺ cations, 240.0 mg, 0.9 mmol) salt was dissolved in deoxygenated MilliQ water (4.5 mL) and mixed with a similar aqueous solution of FeCl₂ • 4H₂O (Fe²⁺ cations, 97.5 mg, 0.45 mmol, 4.5 mL H₂O). This hybrid iron salt aqueous medium (N₂ atmosphere) was first ultrasonicated (Bransonic® ultrasonic cleaner bath, 2510E MTH model, 42 KHz at full power) over a time period of 5 to 10 min at room temperature before introducing 24% of an aqueous NH₄OH (0.75 mL) phase (one shot injection) causing an immediate black precipitation of corresponding magnetite (Fe₃O₄) nanoparticles. The procedure was followed by 19 additional minutes of ultra-sonication. Thus resulting Fe₃O₄ nanoparticles were transferred into a glass bottle (100 mL), magnetically decanted (with a strong external magnet), and washed with ddH₂O (3 x 40 mL) until neutral pH was reached. The resulting black well-dispersed magnetite nanoparticles were stored (30 mL nanoparticles suspension in ddH₂O) before further processing. The ageing storage process was performed for a minimum of 2 h (room temperature) of storage time at room temperature.

Afterwards, the former aqueous magnetite nanoparticles suspension (30 mL, 4.22 h ageing time) was magnetically decanted to separate magnetite nanoparticles from the aqueous phase. Cerium-containing inorganic CAN oxidant reagent [(NH₄)₂Ce(IV)(NO₃)₆], 500.0 mg, 0.912 mmol was dissolved in 6.0 mL of acetone and introduced to the decanted magnetite nanoparticles, followed by an addition of 18 mL of degassed MilliQ water. Finally, the corresponding multi-phase mixture was ultrasonicated using a high-power sonicator (Sonics®, Vibra cell, 750 Watt, power modulator set-up at 25%) - Titanium horn (0.5 h, 0°C - Inert argon atmosphere).

2.3. Preparation of theranostic core particles

To prepare the theranostic core particle, an amount of 25 mg of HSA (fraction V, purity 96–99%) was dissolved in 0.125 mL of MilliQ water and 0.25 ml of a dialysed NGF solution (1 mg/ml) was added. Afterwards, 10 µL of a 1 M sodium chloride solution and 101 µL of a CAN-Fe₂O₃ suspension comprising 0.5 mg of iron were added. The pH was adjusted to 8.0 and the suspension was divided into 2 batches. To each batch, a total amount of 2 mL of ethanol 96% (v/v) was added using a peristaltic pump (Ismatec Laboratoriumstechnik GmbH, Wertheim, Germany) at a rate of 1.1 mL/min while

stirring the dispersion continuously at 400 rpm on a magnetic stirring plate. Finally, a stoichiometric amount of glutaraldehyde corresponding to the number of amino groups in the HSA molecule was added to crosslink the protein. Again, the particle suspension was continuously stirred for 4 hours. The nanoparticles were centrifuged using an Eppendorf centrifuge 5424 R (Eppendorf AG, Hamburg, Germany) at 20,000 rpm for 25 min, washed three times and redispersed in MilliQ water or phosphate buffered saline (pH=7.4, PBS).

2.4. Surface modification of theranostic core particles

The surface of theranostic HSA nanoparticles was modified as described previously [11, 12]. For this purpose, the nanoparticles were activated using the bi-functional crosslinker MALHEX-NH-PEG-NHS. After thiolation of the ligand, ApoE was conjugated to the particle surface using the maleimide active group of the crosslinking agent.

In brief, an amount of 20 mg of the theranostic core particles in 1.0 mL of PBS (pH 8.0) was mixed with 1.0 mL of PBS (pH 8.0) that contained a 10-fold molar excess of MALHEX-NH-PEG-NHS. The suspension was agitated for 1 hour (600 rpm, 20 °C) in a thermomixer (Eppendorf AG, Hamburg, Germany). Afterwards, the suspension was dialysed against 250 ml MilliQ water for 2 hours and against 400.0 ml of 0.1 M NaHCO₃ buffer (pH 8.0) for 2 hours, respectively. In both cases, a dialysis membrane with a molecular weight cut-off (MWCO) of 10 kDa was used.

The thiolation of ApoE was achieved by incubating 1.0 mg of the protein with a 50-fold molar excess of Traut's reagent in PBS over a time period of 2 hours at 600 rpm in a thermomixer (Eppendorf AG, Hamburg, Germany). Afterwards, ApoE was dialyzed against 200 ml MilliQ water using a membrane with 3.5 kDa MWCO for 2 hours and against 200.0 ml 0.1 M NaHCO₃ buffer (pH 8.0) for 2 hours, respectively.

Finally, the ApoE solution was incubated with the activated theranostic core particles for 18 h at 600 rpm and 20 °C in a thermomixer system (Eppendorf AG, Hamburg, Germany). The resulting targeted theranostic particles were dialyzed against 500.0 ml of MilliQ water using a membrane with a MWCO of 100 kDa for 2 hours.

For the cell-based *in vitro* assays, targeted theranostic nanocarriers were labelled using the amino-reactive fluorescent dye ATTO-647N. In this context, 0.5 mg of the nanoparticles in PBS (0.5 ml, pH 8.0) was mixed with 0.065 mL of an ATTO-647N solution in DMSO (0.1 mg/ml), and agitated for 50 min at 600 rpm and 20 °C in a

thermomixer (Eppendorf AG, Hamburg, Germany). The nanoparticles were purified by repeated steps of centrifugation (25 min, 20,000 rpm, centrifuge 5424 R, Eppendorf AG, Hamburg, Germany) and redispersion in MilliQ water.

As a control, HSA nanoparticles carrying PEG chains on their surface were prepared using the mono-functional crosslinking agent mPEG-SPA-5000 to the particle surface under similar conditions.

2.5. Characterization of theranostic particles

The morphology of targeted theranostic nanocarriers was investigated using a FEI Morgagni 268D transmission electron microscope (FEI, Hillsboro, USA).

The particle size and size distribution were determined using the dynamic light scattering method with a Zetasizer Nano ZS (Malvern Instruments, Malvern, UK) equipped with a backscatter detector at an angle of 173°. The particles were characterized for the volume mean diameter and polydispersity index (PDI).

2.6. Storage stability of theranostic particles

To convert the targeted theranostic nanocarriers into a stable solid, form freeze-drying was applied. Mannitol, sucrose, and trehalose were evaluated as lyoprotectants at a concentration of 3% (w/v). For this purpose, a volume of 1.0 mL containing 10 mg/mL of targeted theranostic particles and a lyoprotectant was freeze-dried in a Christ Epsilon 2–7 freeze dryer (Martin Christ GmbH, Osterrode, Germany) as described previously [22, 30]. The physical stability of the targeted theranostic nanocarriers was investigated after 6 months of storage at 4 °C and reconstitution in the same volume of MilliQ water. The dynamic light scattering method was used to evaluate the size change due to the lyophilisation.

2.7. Magnetization of theranostic nanocarriers

The specific (mass dependant) magnetization of the freeze-dried targeted theranostic nanocarriers was determined using a superconducting quantum interference device (SQUID) magnetometer (Quantum Design Inc., San Diego, USA). The samples were fixed in a gelatine capsule and pulled through the induction coils (vibrating sample mode) of the magnetometer at constant temperature (300 K) and various constant external fields.

2.8. Determination of iron content of theranostic particles

The iron content of the theranostic nanocarriers was quantified by inductively coupled plasma optical emission spectroscopy (ICP-OES) using a Spectro Genesis simultaneous spectrometer with axial plasma observation (Spectro Analytical Instruments GmbH, Kleve, Germany).

Multi-elemental standard solutions for ICP calibration (Merck KGaA, Darmstadt, Germany) was used for calibration. The detection limit of iron was calculated according to equation 1:

$$(1) \quad \text{Limit of detection} = \text{Background signal} + 3 * SD_{\text{Background}} * f_{\text{dilution}}$$

A known amount of theranostic nanocarriers was dissolved in 5 M hydrochloric acid and diluted to be in the applied calibration range.

2.9. Release from the HSA nanoparticle system using the dispersion releaser technology

The release from HSA nanoparticles was determined using the dialysis-based dispersion releaser technology as described earlier by Janas *et al.* [26]. Since the testing requires relevant amounts of the protein, trypsinogen (molecular weight 24 kDa, isoelectric point 9.3) was selected as a model protein for NGF (molecular weight 26 kDa, isoelectric point 9.3).

For this purpose, the protein was labelled using a 3-fold molar excess of ATTO-647-N-hydroxysuccinimide. Unbound fluorescent label was separated from labelled protein by using G-25 Sephadex size exclusion chromatography column (GE Healthcare Life Sciences, Buckinghamshire, UK). Subsequently diluted protein solutions obtained were concentrated by using Amicon Ultra centrifugal protein concentrators (Sigma Aldrich, Darmstadt, Germany). Desolvation and particle purification was carried as described in the section 2.3 above.

The purified particles were redispersed in 1 ml of MilliQ water and a volume of 300 µl was introduced to the donor compartment. Acceptor medium for the release study was PBS. A semipermeable 100 kDa cellulose ester dialysis membrane was used to separate donor and acceptor compartment of the dispersion releaser. Volumes of 500 µl were collected at predefined time points from the acceptor compartment. After 6 hours, a small quantity (approximately 15 units of enzyme in 50 µl of volume) of

proteinase K solution was added to the donor compartment to change from a diffusion-based to a degradation-based release mechanism [31].

2.10. PC12 cytotoxicity and cellular bioactivity assay

PC12 cells were cultured with Dulbecco's modified Eagle's medium containing 5% (v/v) fetal bovine serum (FBS), 10% (v/v) horse serum, and 1% (v/v) penicillin–streptomycin (37 °C, 5% CO₂). The cytocompatibility of targeted theranostic nanocarriers was analysed using an 3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay in PC12 cells. Pre-cultured cells were seeded at a density of 5×10^4 per well in a 96-well plate and cultured for 24 h. An amount of 10, 25 and 50 µg of targeted theranostic nanocarriers was added to each well in a volume of 5 µl of PBS. The cells were incubated for 24, 48, and 72 h. A volume of 20 µl (10 % v/v) containing 5 mg/ml of MTT solution was added followed by incubation over 30 minutes. After removing the medium, the cells were lysed, and the absorbance of lysates was determined at 595 nm using an EnVision 2104 multilabel reader (Perkin Elmer Inc., Waltham, USA). The percentage of viable cells was calculated in comparison to the untreated cells (control).

In addition, the bioactivity of NGF via the outgrowth of neurites from PC12 cells to neural phenotype upon exposure to NGF was investigated. The PC12 cell differentiation assay has been applied to test the activity of NGF earlier (Johnson et al. 2008). The cells grow neurites when exposed to NGF at concentration higher than approximately 10 ng/mL [32]. For this purpose, 5×10^4 cells per well were seeded in 24-well plates. NGF solution in PBS containing residues of poly ethylene glycol, HSA nanoparticles without NGF and PBS solution were used as controls. All reference samples containing NGF were studied with the following NGF at concentrations of 6.25 ng/ml, 12.5 ng/ml, 25 ng/ml, 50 ng/ml, 100 ng/ml, 500 ng/ml, 1000 ng/mL. Neurite outgrowth was examined and imaged by phase-contrast microscopy, and representative cells were photographed with a CCD camera (Zeiss, Oberkochen, Germany) after 3 days of exposure to the nanocarriers or pure growth factor.

2.11. Transport studies of theranostic nanoparticles using an in vitro BBB model

A number of 10,000 bEND3 cells were seeded in a 100 μ l culture medium on 24 well 1 μ m ThinCerts which were precoated with 100 μ l FBS for 30 min. In the lower compartment (basolateral), 1 ml of culture medium, 10% FBS (heat inactivated), L-glutamine and Na-pyruvate was added. As a control, half of the ThinCerts were not seeded with cells. ThinCerts with and without cells were incubated in the laminar flow bench at room temperature for one hour (to allow cells settling down) and subsequently for two hours at 37°C. Afterwards, they were transferred to the cellZscope2 (nanoAnalytics, Münster, Germany). Two hundred microliters of medium were added to the ThinCerts to reach a final volume of 300 μ l in the upper compartment (apical). The transendothelial electrical resistance (TER) and capacitance were measured every hour for 5 days. After 5 days the medium was changed to DMEM with 2 % FBS, 2 mM L-glutamine, Na-pyruvate and 110 nM hydrocortisone. Hydrocortisone was added to increase and to stabilize the TER value. The TER and capacitance values were measured every hour for 1 day. A volume of 17 μ l of the theranostic targeted nanoparticles, as well as the PEGylated reference formulation (without ApoE coating) were added to the cells (apical). The TER and capacitance values were recorded every 30 minutes for one day. A volume of 200 μ l of the nanoparticle samples (basolateral) were transferred to a black 96 well plate and measured in a plate reader using an excitation wavelength of 646 nm and an emission wavelength of 664 nm (ENSPiRE® Multimode plate reader, Perkin Elmer, Waltham, USA).

2.12. Ethics

All experiments were carried out in strict accordance with the guidelines for the European Community Council directive (2010/63/EU) for protection of vertebrate animals used for experimental and other scientific purposes. The surgeries were approved by Lund County Administrative Court under the auspices of the Swedish Department of Agriculture (M188-12). The study complies with the ARRIVE guidelines (Animal Research: Reporting *In Vivo* Experiments).

2.13. Animals and treatments

Male Wistar rats obtained from Janvier were used for the experiments. Transient middle cerebral artery occlusion (tMCAO) model was induced for 2 hours followed by reperfusion. All animals were randomly divided into 3 groups; (i) vehicle treated, (ii) treated with U0126 and (iii) treated with NGF in combination with U0126. The MEK1/2 inhibitor U0126 was given at 0 and 24 h post reperfusion and NGF was given at day 3 post-stroke. Animals were randomly selected for treatment that was blinded to the operator.

2.14. Transient middle cerebral artery occlusion model

The experimental stroke model was performed by using an intraluminal filament technique [33] to induce transient middle cerebral artery occlusion in male Wistar rats. Anesthesia was induced by 3.5% isoflurane in N₂O:O₂ (70:30) and then maintained by inhalation of 1.5-2% isoflurane in N₂O:O₂ (70:30) during the surgical procedure. The measurement of blood pressure, pH, pCO₂, pO₂ and blood glucose was performed prior to the occlusion. To maintain body temperature during the surgical procedure a rectal temperature probe connected to a homoeothermic blanket was used. An incision was made in the midline of the neck, and the right common, internal and external carotid arteries were exposed. The right common and external carotid arteries were ligated permanently with sutures. A silicon rubber-coated monofilament (Dccol Corporation, Sharon, USA) was inserted into the right internal carotid artery and further advanced until the tip of the filament reached the entrance of the middle cerebral artery. The resulting occlusion was confirmed by Laser-Doppler flowmetry. Average Laser-Doppler flow reductions of cerebral blood flow were 71± 2%. Following insertion of the filament the rats were sewed and regained consciousness. Two hours after occlusion, the rats were re-anesthetized and the filament removed to achieve reperfusion as verified by Laser-Doppler flowmetry. At the end of the surgery, the rats received a subcutaneous injection of 10 ml of isotonic saline for hydration.

2.15. Pre-clinical MR imaging at 9.4T to evaluate infarct volume

MRI monitoring was performed at day 14 post-stroke on a 9.4 T preclinical MRI horizontal bore scanner (Biospec Bruker, Billerica, USA) in conjunction with the 205/120 HD gradient coil unit. During the imaging procedure, the breathing rate and body temperature were monitored. The imaging was performed accordingly to

previous described protocols [29]. The ^1H T₂-weighted images were acquired to measure the infarct volume. Images were analyzed using a self-written script in Matlab® (Natick, Massachusetts, USA). The region of interest (ROI) corresponding to the whole ischemic lesion was manually delineated by an operator blinded to the treatment group and the extension of damage was reported as infarct volume (mm³).

2.16. Statistics

All outcomes were expressed as the mean value \pm standard deviation (SD). The experiments (except the preformulation studies) were performed in triplicate at least (single experiments are indicated in the figure legend). The mean value and SD were analyzed by using Microsoft Excel (Microsoft, Redmond, USA). Particle characterization data was analyzed and illustrated using SigmaPlot 17.0 (Systat Software GmbH, Germany). Statistical significance of various processes on particle size and *in vivo* experiments was analyzed using a one-way ANOVA test. Where indicated different statistical tests were used.

3. Results

Theranostic NGF-loaded nanocarriers were manufactured by embedding USPIO and NGF into HSA core particles followed by surface modification with ApoE. The release of NGF was investigated with the help of the dispersion releaser technology [26]. The nanocarriers were evaluated for NGF bioactivity and cytotoxicity in PC12 cells and the transport through the BBB was studied *in vitro* using bEnd3 cells. The effect of a combination treatment of NGF with the small-molecular MEK inhibitor U0126 was studied in an animal model of stroke.

3.1. Preparation of advanced NGF-loaded theranostic nanocarriers

The diagnostic MRI-enabling maghemite (γ - Fe_2O_3)-based iron oxide particles were synthesized by two consecutive nanofabrication steps, the preparation of ultra-small basic Massart magnetite (Fe_3O_4) nanoparticles followed by an optimized surface engineering method as described previously [23]. The nanoparticles were characterized for size by transmission electron microscopy (TEM) (6.61 ± 2.04) and by DLS (60 ± 2 nm, 0.136) as presented in Figure 1. It should be noted that, the hydrodynamic diameter measured by DLS is systemically larger than the one observed in TEM micrographs [34].




Figure 1: Standard (A) and high-resolution (B) transmission electron micrograph, selected diffraction (SAED) pattern (C) and size distribution histogram (D) of ultra-small 6.61 ± 2.04 nm-sized USPIO.

A zeta potential value of $+45.7 \pm 1.88$ mV together with a Ce/Fe ratio of 0.1000 was obtained. To encapsulate USPIO into albumin nanocarriers, the desolvation method was applied [35]. Presumably both, a positive surface charge and $\text{Ce}^{3/4+}$ cations coordinative linkage led to a strong interaction with the negatively charged matrix material [22].

In previous designs, the HSA-CAN maghemite hybrid particles were optimized with an average diameter of 170 ± 10 nm [21]. However, particle size differed significantly, when NGF was present. When adjusting an initial iron content of 1 % (m/m) a particle size between 141 ± 1 nm (pH 6.5) and 207 ± 1 nm (pH 8.5) was obtained (see Figure 2, left). Elevated pH values resulted in a considerable reduction of the particle yield, which was even more pronounced in presence of sodium chloride. Therefore, nanoparticle synthesis was conducted in absence in sodium chloride

Finally, theranostic nanocarriers were synthesized at a pH of 8.0. The HSA nanoparticles exhibited a hydrodynamic diameter of 152 ± 6 nm (PDI 0.037 ± 0.009) and a particle yield of 75.3 ± 4.9 % yield (m/m). A zeta potential of -47.7 ± 1.4 mV indicated high physical stability of the dispersion. In presence of NGF, a particle diameter of 191 ± 2 nm (PDI 0.021 ± 0.017) with a particle yield of 71.5 % (m/m) and a zeta potential of -48.3 mV was obtained.




Figure 2: Particle size, particle yield, and polydispersity index of nanoparticles in the preformulation studies (left) synthesized at different pH values (particle size: light green bar, particle yield: dark green bar, PDI: white dot) ($n=1$). Particle size and polydispersity index of nanoparticles (right) before (particle size: light green bar, PDI: white dot) and after (particle size: dark green bar, PDI: white triangle) lyophilisation using mannitol, sucrose or trehalose as a lyoprotector ($n=3$, mean \pm SD).

The conjugation with ApoE resulted in a slight but not significant (ANOVA) increase in particle size to 212 ± 1 nm (PDI 0.075 ± 0.022).

Morphology of the targeted theranostic nanocarriers was explored by TEM. As expected, USPIO were embedded into the spherical cross-linked matrix system comprising HSA and NGF (see Figure 3). Finally, the magnetization of the theranostic nanocarriers, that contained 1.6 % (w/w) and 4.6 % (w/w) iron, was examined using a SQUID magnetometer. Converting the iron content to 100 % of CAN-maghemite the resulting saturation magnetization values (53.0 emu/g and 54.1 emu/g) were comparable to those of CAN-maghemite (59.5 emu/g).




Figure 3: Transmission electron micrograph of targeted theranostic nanocarriers at 10000-fold (A) and 20,000-fold (B) magnification.

3.2. Storage stability of nanosuspensions after freeze drying

The initial formulation studies revealed a lyoprotector concentration of 3% as beneficial for the lyophilisation process. Therefore, the hybrid particles were freeze-dried in presence of 3% (w/v) mannitol, sucrose and trehalose at a nanoparticle concentration of 10 mg/ml and tested for their physical stability after 6 months of storage at 4 °C and redispersion in MilliQ water. In the presence of sucrose and trehalose, the stability was maintained as indicated by particle size and PDI (see Figure 2, right). However, in the presence of mannitol, the particle size and PDI were considerably increased. Therefore, for further studies, all preparations were freeze-dried in the presence of sucrose.

3.3. *In vitro* characterization of theranostic nanocarrier formulations

To exclude acute toxicity of the novel albumin-based targeted nanocomposites, the biocompatibility was tested. Cell viability was compared to a reference of untreated cells after an incubation time of 24, 48 and 72 h (see Figure 4).




Figure 4: Cell viability of PC12 cells treated with 100 ng, 250 ng and 500 ng of NGF as well as 10 µg, 25 µg, and 50 µg of NGF-loaded nanoparticles after 24, 48 and 72 h of incubation. The viable cell mass was measured by the MTT assay. (n=4, mean ± SD).

This investigation was complemented by an evaluation of the bioactivity of NGF after encapsulation into the nanocarrier system. After several steps of processing including desolvation, chemical crosslinking, the surface modification, and lyophilisation, an influence on the bioactivity of the growth factor was assumed. The capacity of PC12 cells for neurite outgrowth has been used this way earlier [32].

Interestingly, the surface modification of NGF with polyethylene glycol (PEG) contributed to an enhanced stability of the protein [32] (see Figure 5D). The processing of NGF resulted in a substantial loss of biological activity. Neurite outgrowth was observed at more than an order of magnitude higher theoretical NGF concentration

(500 ng/ml, see Figure 5 F) in comparison to NGF solution or lyophilised and reconstituted NGF (12.5 ng/ml, see Figure 5 B,D).

To investigate the reasons behind the reduced activity, a drug release study was conducted using the dispersion releaser technology [26]. Compared to other methods, the dialysis-based setup allows a highly sensitive and reproducible measurement even in presence of serum proteins and other biorelevant media [27, 36]. The total drug release remained below 20% during the first 4 hours reaching a maximum value of $17.98 \pm 17.82\%$. After 6 hours, proteinase K was added to the donor compartment in order to change the mechanism of release from diffusion to degradation [31]. As a result, release increased to $32.4 \pm 10.3\%$.




Figure 5: In vitro neurite outgrowth of rat embryonic pheochromocytoma cells (PC12) after incubation with NGF-PEG solution (A: 6.25 ng NGF/well, B: 12.5 ng NGF/well), NGF-PEG lyophilisate solution (C: 6.25 ng NGF/well, D: 12.5 ng NGF/well), HSA-CAN maghemite-NGF-ApoE nanocomposite (E: 100 ng NGF/well, F: 500 ng NGF/well) and blank HSA-CAN maghemite nanocomposite (Control: 50 μ g).

To complement these studies, the transport of nanocarrier formulations through an artificial BBB was investigated *in vitro*. For this purpose, a transwell assay system was applied using a confluent cell layer of the bEnd3 cell line. The TER value was monitored over the time of the experiment. A similar model has been used earlier to confirm the nanocarrier-mediated uptake of drugs into the brain [37]. After 48 h of incubation, the NGF concentration (measured as fluorescence intensity) was significantly higher in the basolateral compartment compared to the reference formulation without ApoE (see Figure 6A).




Figure 6: The penetration potential of nanocarriers was measured by detecting the fluorescence level in the basolateral compartment after 0 h and 48 h. ApoE-coated nanocarriers show an increased penetration in comparison to PEGylated nanocarriers (control). *** $p < 0.001$ indicates significant difference between ApoE-coated and PEGylated nanocarriers (t-test). B) To quantify changes of the TER, TER value 20 h after addition of the formulation (vehicle, ApoE-coated nanocarriers, PEGylated nanocarriers) was related to the TER value before the addition of the nanocarrier. The PEGylated nanocarriers reduce the TER value in comparison to the vehicle-treated control. *** $p < 0.001$ indicates significant difference between nanocarrier treated samples and vehicle treated samples (Bonferroni's multiple comparisons test).

The constant TER value indicated an intact barrier (see Figure 6B), however, there were some minor effects of the reference formulation on barrier integrity observed (see Figure 6B). This was not the case for the ApoE coated particles (see Figure 6B).

3.4. Brain recovery after stroke

Brain recovery after stroke was investigated inducing transient middle cerebral artery occlusion in male Wistar rats as described previously [33]. The brain infarct volume was determined from T₂-weighted magnetic resonance images on day 14 post-stroke (see Figure 7A-C). A vehicle-control (see Figure 7A,D), the small molecule MEK inhibitor U0126 (see Figure 7D) and a combination of U0126 together with the NGF-loaded drug delivery system were tested (see Figure 7C,D).




Figure 7: MR images of infarct site as well as the evaluation of infarct volume post-administration of vehicle control (A,D), U126 (B, D), and NGF-loaded nanocarriers in combination with U0126 (C, D) 14 days after stroke. (n=9, mean \pm SEM); * indicates significant differences between treatment and vehicle treated rats (ANOVA, $p < 0.05$). (Kruskal-Wallis test with Dunn's multiple comparisons analysis)

For the combination treatment using NGF-loaded theranostic nanocarriers and U0126, significant reduction of the infarct size was observed compared to the vehicle control (see Figure 7). U0126 alone also showed a significant reduction of the infarct size, however, there was no significant difference between the two treatments observed (see Figure 77).

4. Discussion

Today, stroke is a leading cause of death globally and is responsible for 9% of all deaths around the world [2]. A family of neurotrophins including NGF is involved in cerebral recovery [38] and was studied as a therapeutic option for brain injury [7]. Moreover, inhibition of MEK, a pathway which is activated following cerebral ischemia [39-42], in the acute phase of stroke, can improve the long-term neurological outcome [29, 43].

Unfortunately, NGF is not able to pass the BBB which effectively controls the cellular and molecular traffic between the brain and the periphery [8, 44]. To bypass this barrier, previous studies utilized infusion into cerebral ventricles leading to a significant

reduction of delayed neuronal death in rats [3]. In a clinical setting, there were two cases of infants reported where the intraventricular administration of NGF showed a beneficial effect on recovery of hypoxic-ischemic brain injuries and cerebral perfusion [4, 5].

Over the years, a broad array of methods has been developed to enhance access of drugs to the brain at therapeutically meaningful concentrations [6, 7]. Nanocarrier delivery turned out to be an alternative to the conventional interventions. PBCA nanoparticles coated with polysorbate 80 were successfully used to deliver NGF to the brain after intravenous injection [13]. The adsorption of apolipoproteins followed by active transport through the BBB are the most likely mechanism [14]. Animals treated with the drug delivery system exhibited improved recognition and memory in the passive avoidance reflex (PAR) test [13].

In another study, transcytosis of targeted HSA nanoparticles through the brain endothelial cells was confirmed *in vitro* [15] and *in vivo* [12]. These particles were modified on their surface with ApoE [12, 15]. Even the short half-life of HSA nanoparticles in blood plasma [45] allowed the delivery system to access all six investigated brain regions [12].

In the present approach, nanocarriers for the treatment of stroke comprising a biodegradable matrix of HSA and NGF were modified on their surface with ApoE in order to deliver the growth factor to the brain. Further, USPIO were embedded into these nanoparticles to introduce diagnostic functionality to the delivery system. With an average diameter of 212 ± 1 nm (PDI 0.075 ± 0.022), the nanoparticles were in a similar size range compared to earlier studies (200-250 nm) [12]. A monodisperse size distribution and optimal storage stability were achieved after freeze drying. As reported earlier, sucrose turned out to be an efficient lyoprotector for protein particles (see Figure 2, right) and was used to convert the liquid into a solid dispersion [30].

To track the *in vivo* biodistribution during later stages of preclinical and clinical translation, USPIO were co-encapsulated into the particle matrix. Initially, CAN maghemite particles were characterized for their particle size and size distribution (see section 3.1). As previously reported, the hydrodynamic diameter of USPIO (measured

by DLS) was significantly larger compared to the one determined by electron microscopy [34].

Afterwards, successful encapsulation into the protein structure was visualized by TEM (see Figure 3). USPIO were homogeneously distributed and saturation magnetization values were comparable to the non-encapsulated suspension. The iron load was even higher compared to current literature [21]. Against this background, the particles might be suitable for MRI applications as required to explore biodistribution patterns [21].

As a next step, the toxicity and bioactivity of NGF-loaded nanocarriers was determined *in vitro*. After three days of incubation, the neurotrophin as well as the NGF-loaded nanocarriers induced neurite outgrowth in PC12 cells [32] suggesting that NGF remained active through the encapsulation procedure and was released from the carrier. Compared to NGF, the extent of this outgrowth was lowered for the nanoparticles (see Figure 5). The assay provides only semiquantitative information and more efforts will be made to study structure-activity relationships of the nanosystem. A delayed release of NGF from the carrier as well as a lowered activity following the processing and chemical modification of the protein can be assumed.

The *in vitro* release was studied using the dispersion releaser technology [26]. It remained below 20% during the first 4 hours ($17.98 \pm 17.82\%$). However, there was also a high variability observed between the three vessels which was in line with the rather complex release mechanism assumed for the carrier. With a molecular weight of approximately 24 kDa the utilized model protein (trypsinogen) presumably had multiple interactions with the particle surface and pore structure of the nanocarrier which can lead to altered release patterns. After 6 hours, the release mechanism was shifted to a degradation-based release by adding proteinase K to the donor compartment. Degradation of HSA nanoparticles in presence of the enzyme has been studied previously [31]. A maximum release of $32.41 \pm 10.35\%$ was achieved. The results confirm the outcome of the bioactivity assay showing a lowered activity but also explain the difficulties of applying *in vitro* findings to the *in vivo* situation. Further investigations of drug release as well as an optimization of the formulation parameters may be necessary.

A number of studies suggested the delivery of NGF after transcytosis of the ApoE-coated nanoparticles through the BBB [11, 12, 15]. The LRP1 receptor was held responsible for this uptake [15]. In the present investigation, the transport of nanocarriers was investigated *in vitro* using a transwell assay system and bEnd3 cells [37]. After 48 h the NGF concentration was significantly higher in the basolateral compartment for the ApoE-coated particles compared to the reference formulation (see Figure 6A). The TER value was slightly lowered for the control, indicating an influence of the reference on the barrier properties (see Figure 6B). Generally speaking, there are more advanced models of the BBB necessary, to detect the influence of slight formulation changes on drug transport [15]. For the ApoE-coated nanocarrier formulation a TER value of $79.81 \pm 8.58 \Omega \cdot \text{cm}^2$ was found. For comparison, in the *in vivo* setting, a TER value of $5900 \Omega \cdot \text{cm}^2$ has been detected. More recent cell-based models of the BBB achieve TER values of more than $500 \Omega \cdot \text{cm}^2$ [46]. However, using this model a transport mechanism was confirmed which has been reported for ApoE-coated particles in a number of studies [15, 47, 48].

Finally, the efficacy of NGF-loaded nanocarriers was tested in combination with the small molecular MEK inhibitor U0126 in the transient middle cerebral artery occlusion in male Wistar rats [33]. The infarct size was significantly reduced compared to the vehicle control for the combination therapy as well as for U0126 alone.

Unfortunately, there was only a slight but not significant difference observed in the infarct size between the two therapies (combination and U0126 alone), presumably due to the small group size (see Figure 77). However, this trend was confirmed by the neurologic examination following the well-established 6-point and 28-point scoring systems [49-51] (Data not shown). This clearly suggests the effective delivery of NGF to the brain as well as a synergistic effect of the neuropeptide with the MEK inhibitor. The outcome of the neurologic examination and the histological evaluation will be published in a separate manuscript (Ansar et al. 2018, Manuscript in preparation). Further research will investigate the biodistribution of these theranostic nanocarriers using their superparamagnetic properties. Additionally, the therapeutic effect of NGF-loaded nanocarriers will be tested alone to learn more about the mechanisms underlying this synergistic neuroprotection.

5. Conclusions

The presence of the BBB poses an obstacle to drug delivery. Over the years, ways have been discovered to address specific transport mechanisms on the surface of the brain endothelial cells allowing therapeutics to enter the CNS. In the present study, we successfully encapsulated NGF and USPIO into an albumin matrix. These nanocomposites with a size of approximately 200 nm attained their superparamagnetic properties and exhibited low toxicity. After modification of the particle surface with ApoE, the particles were able to cross an artificial BBB and remained bioactive in terms of the regulation of neurite outgrowth. In an animal model of stroke, a slight reduction of the infarct volume indicated a synergistic therapeutic effect of NGF and the small-molecular MEK inhibitor U0126. The trend was also confirmed by an in-depth investigation of the neuroscore that will be published by Ansar and co-workers (manuscript in preparation). Further research will be necessary to study the biodistribution of this nanocarrier system as well as to understand the mechanisms underlying these observations.

6. Acknowledgements

The authors acknowledge Dr. Bernd Wolf for the SQUID measurements at the Institute of Physics (Goethe University, Frankfurt, Germany) as well as the Alexander von Humboldt Foundation (Ref. No.: 3.3-UNG/1161203 STP and 3.3-1161203-HUN-HFST-E), the BIONANO_GINOP-2.3.2-15-2016-00017 project, the Swedish Heart-Lung Foundation and the LOEWE Research Centre for Translational Medicine and Pharmacology of the state of Hessen for financial support.

7. References

- [1] L. Aloe, M.L. Rocco, B.O. Balzamino, A. Micera, Nerve Growth Factor: A Focus on Neuroscience and Therapy, *Curr Neuropharmacol*, 13 (2015) 294-303.
- [2] G.A. Donnan, M. Fisher, M. Macleod, S.M. Davis, Stroke, *The Lancet*, 371 (2008) 1612-1623.
- [3] T. Shigeno, T. Mima, K. Takakura, D. Graham, G. Kato, Y. Hashimoto, S. Furukawa, Amelioration of delayed neuronal death in the hippocampus by nerve growth factor, *The Journal of Neuroscience*, 11 (1991) 2914-2919.
- [4] A. Chiaretti, O. Genovese, R. Riccardi, C. Di Rocco, D. Di Giuda, P. Mariotti, S. Pulitano, M. Piastra, G. Polidori, G.S. Colafati, L. Aloe, Intraventricular nerve growth

factor infusion: a possible treatment for neurological deficits following hypoxic-ischemic brain injury in infants, *Neurological research*, 27 (2005) 741-746.

[5] C. Fantacci, D. Capozzi, P. Ferrara, A. Chiaretti, Neuroprotective role of nerve growth factor in hypoxic-ischemic brain injury, *Brain sciences*, 3 (2013) 1013-1022.

[6] L.T. Bonner, E.R. Peskind, Pharmacologic treatments of dementia, *Med Clin North Am*, 86 (2002) 657-674.

[7] P.M. Friden, L.R. Walus, P. Watson, S.R. Doctrow, J.W. Kozarich, C. Backman, H. Bergman, B. Hoffer, F. Bloom, A.C. Granholm, Blood-brain barrier penetration and in vivo activity of an NGF conjugate, *Science (New York, N.Y.)*, 259 (1993) 373-377.

[8] D.J. Begley, ABC transporters and the blood-brain barrier, *Curr Pharm Des*, 10 (2004) 1295-1312.

[9] K. Ulbrich, T. Hekmatara, E. Herbert, J. Kreuter, Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB), *Eur J Pharm Biopharm*, 71 (2009) 251-256.

[10] K. Ulbrich, T. Knobloch, J. Kreuter, Targeting the insulin receptor: nanoparticles for drug delivery across the blood-brain barrier (BBB), *J Drug Target*, 19 (2011) 125-132.

[11] A. Zensi, D. Begley, C. Pontikis, C. Legros, L. Mihoreanu, C. Buchel, J. Kreuter, Human serum albumin nanoparticles modified with apolipoprotein A-I cross the blood-brain barrier and enter the rodent brain, *J Drug Target*, 18 (2010) 842-848.

[12] A. Zensi, D. Begley, C. Pontikis, C. Legros, L. Mihoreanu, S. Wagner, C. Buchel, H. von Briesen, J. Kreuter, Albumin nanoparticles targeted with ApoE enter the CNS by transcytosis and are delivered to neurones, *J Control Release*, 137 (2009) 78-86.

[13] K.B. Kurakhmaeva, I.A. Djindjikhshvili, V.E. Petrov, V.U. Balabanyan, T.A. Voronina, S.S. Trofimov, J. Kreuter, S. Gelperina, D. Begley, R.N. Alyautdin, Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles, *J Drug Target*, 17 (2009) 564-574.

[14] J. Kreuter, D. Shamenkov, V. Petrov, P. Ramge, K. Cychutek, C. Koch-Brandt, R. Alyautdin, Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier, *J Drug Target*, 10 (2002) 317-325.

[15] S. Wagner, A. Zensi, S.L. Wien, S.E. Tschickardt, W. Maier, T. Vogel, F. Worek, C.U. Pietrzik, J. Kreuter, H. von Briesen, Uptake mechanism of ApoE-modified nanoparticles on brain capillary endothelial cells as a blood-brain barrier model, *PLoS One*, 7 (2012) e32568.

[16] S. Gaca, S. Reichert, G. Multhoff, M. Wacker, S. Hehlhans, C. Botzler, M. Gehrmann, C. Rodel, J. Kreuter, F. Rodel, Targeting by cmHsp70.1-antibody coated and survivin miRNA plasmid loaded nanoparticles to radiosensitize glioblastoma cells, *J Control Release*, 172 (2013) 201-206.

[17] I.M. Steinhauser, K. Langer, K.M. Strebhardt, B. Spankuch, Effect of trastuzumab-modified antisense oligonucleotide-loaded human serum albumin nanoparticles prepared by heat denaturation, *Biomaterials*, 29 (2008) 4022-4028.

[18] M.G. Anhorn, H.C. Mahler, K. Langer, Freeze drying of human serum albumin (HSA) nanoparticles with different excipients, *Int J Pharm*, 363 (2008) 162-169.

[19] S. Dreis, F. Rothweiler, M. Michaelis, J. Cinatl, Jr., J. Kreuter, K. Langer, Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles, *Int J Pharm*, 341 (2007) 207-214.

[20] J.Y. Lee, K.H. Bae, J.S. Kim, Y.S. Nam, T.G. Park, Intracellular delivery of paclitaxel using oil-free, shell cross-linked HSA--multi-armed PEG nanocapsules, *Biomaterials*, 32 (2011) 8635-8644.

- [21] I. Rosenberger, C. Schmithals, J. Vandooren, S. Bianchessi, P. Milani, E. Locatelli, L.L. Israel, F. Hubner, M. Matteoli, J.P. Lellouche, M.C. Franchini, L. Passoni, E. Scanziani, G. Opdenakker, A. Piiper, J. Kreuter, Physico-chemical and toxicological characterization of iron-containing albumin nanoparticles as platforms for medical imaging, *J Control Release*, 194 (2014) 130-137.
- [22] M.G. Wacker, M. Altinok, S. Urfels, J. Bauer, Nanoencapsulation of ultra-small superparamagnetic particles of iron oxide into human serum albumin nanoparticles, *Beilstein J Nanotechnol*, 5 (2014) 2259-2266.
- [23] A.H. Haviv, J.M. Greneche, J.P. Lellouche, Aggregation control of hydrophilic maghemite ($\gamma\text{-Fe}_2\text{O}_3$) nanoparticles by surface doping using cerium atoms, *J Am Chem Soc*, 132 (2010) 12519-12521.
- [24] L.L. Israel, E. Lellouche, S. Ostrovsky, V. Yarmiayev, M. Bechor, S. Michaeli, J.P. Lellouche, Acute in vivo toxicity mitigation of PEI-coated maghemite nanoparticles using controlled oxidation and surface modifications toward siRNA delivery, *ACS Appl Mater Interfaces*, 7 (2015) 15240-15255.
- [25] J.P. Lellouche, S. Michaeli, L.L. Israel, E. Lellouche, K. Buchman, Magnetic Inorganic Iron-Based Nanoparticles - Generalities and Use in Drug Delivery, in, 2014.
- [26] C. Janas, M.P. Mast, L. Kirsamer, C. Angioni, F. Gao, W. Mantele, J. Dressman, M.G. Wacker, The dispersion releaser technology is an effective method for testing drug release from nanosized drug carriers, *Eur J Pharm Biopharm*, 115 (2017) 73-83.
- [27] F. Jung, L. Nothnagel, F. Gao, M. Thurn, V. Vogel, M.G. Wacker, A comparison of two biorelevant in vitro drug release methods for nanotherapeutics based on advanced physiologically-based pharmacokinetic modelling, *Eur J Pharm Biopharm*, 127 (2018) 462-470.
- [28] H. Ahnstedt, M. Mostajeran, F.W. Blixt, K. Warfvinge, S. Ansar, D.N. Krause, L. Edvinsson, U0126 attenuates cerebral vasoconstriction and improves long-term neurologic outcome after stroke in female rats, *J Cereb Blood Flow Metab*, 35 (2015) 454-460.
- [29] M. Mostajeran, L. Edvinsson, K. Warfvinge, R. Singh, S. Ansar, Inhibition of mitogen-activated protein kinase 1/2 in the acute phase of stroke improves long-term neurological outcome and promotes recovery processes in rats, *Acta Physiol (Oxf)*, 219 (2017) 814-824.
- [30] M. Wacker, K. Chen, A. Preuss, K. Possemeyer, B. Roeder, K. Langer, Photosensitizer loaded HSA nanoparticles. I: Preparation and photophysical properties, *Int J Pharm*, 393 (2010) 253-262.
- [31] K. Langer, M.G. Anhorn, I. Steinhauser, S. Dreis, D. Celebi, N. Schrickel, S. Faust, V. Vogel, Human serum albumin (HSA) nanoparticles: reproducibility of preparation process and kinetics of enzymatic degradation, *Int J Pharm*, 347 (2008) 109-117.
- [32] P.J. Johnson, S.L. Skornia, S.E. Stabenfeldt, R.K. Willits, Maintaining bioactivity of NGF for controlled release from PLGA using PEG, *J Biomed Mater Res A*, 86 (2008) 420-427.
- [33] H. Memezawa, H. Minamisawa, M.L. Smith, B.K. Siesjo, Ischemic penumbra in a model of reversible middle cerebral artery occlusion in the rat, *Exp Brain Res*, 89 (1992) 67-78.
- [34] J. Lim, S.P. Yeap, H.X. Che, S.C. Low, Characterization of magnetic nanoparticle by dynamic light scattering, *Nanoscale Research Letters*, 8 (2013) 381-381.
- [35] C. Weber, J. Kreuter, K. Langer, Desolvation process and surface characteristics of HSA-nanoparticles, *Int J Pharm*, 196 (2000) 197-200.
- [36] M. Villa Nova, C. Janas, M. Schmidt, T. Ulshoefer, S. Grafe, S. Schiffmann, N. de Bruin, A. Wiehe, V. Albrecht, M.J. Parnham, M. Luciano Bruschi, M.G. Wacker,

Nanocarriers for photodynamic therapy-rational formulation design and medium-scale manufacture, *Int J Pharm*, 491 (2015) 250-260.

[37] S. Meister, I. Zlatev, J. Stab, D. Docter, S. Baches, R.H. Stauber, M. Deutsch, R. Schmidt, S. Ropele, M. Windisch, K. Langer, S. Wagner, H. von Briesen, S. Weggen, C.U. Pietrzik, Nanoparticulate flurbiprofen reduces amyloid-beta42 generation in an in vitro blood-brain barrier model, *Alzheimers Res Ther*, 5 (2013) 51.

[38] I.N. Solev, V.Y. Balabanyan, I.A. Volchek, O.S. Elizarova, S.A. Litvinova, T.L. Garibova, T.A. Voronina, Involvement of BDNF and NGF in the mechanism of neuroprotective effect of human recombinant erythropoietin nanoforms, *Bulletin of experimental biology and medicine*, 155 (2013) 242-244.

[39] J. Xing, J.M. Kornhauser, Z. Xia, E.A. Thiele, M.E. Greenberg, Nerve growth factor activates extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways to stimulate CREB serine 133 phosphorylation, *Molecular and cellular biology*, 18 (1998) 1946-1955.

[40] S. Namura, K. Iihara, S. Takami, I. Nagata, H. Kikuchi, K. Matsushita, M.A. Moskowitz, J.V. Bonventre, A. Alessandrini, Intravenous administration of MEK inhibitor U0126 affords brain protection against forebrain ischemia and focal cerebral ischemia, *Proc Natl Acad Sci U S A*, 98 (2001) 11569-11574.

[41] N. Sawe, G. Steinberg, H. Zhao, Dual roles of the MAPK/ERK1/2 cell signaling pathway after stroke, *J Neurosci Res*, 86 (2008) 1659-1669.

[42] G. Sun, N. Ye, D. Dai, Y. Chen, C. Li, Y. Sun, The Protective Role of the TOPK/PBK Pathway in Myocardial Ischemia/Reperfusion and H₂O₂-Induced Injury in H9C2 Cardiomyocytes, *Int J Mol Sci*, 17 (2016) 267.

[43] L.I. Edvinsson, G.K. Povlsen, Vascular plasticity in cerebrovascular disorders, *J Cereb Blood Flow Metab*, 31 (2011) 1554-1571.

[44] A. Nyul-Toth, M. Suci, J. Molnar, C. Fazakas, J. Hasko, H. Herman, A.E. Farkas, J. Kaszaki, A. Hermenean, I. Wilhelm, I.A. Krizbai, Differences in the molecular structure of the blood-brain barrier in the cerebral cortex and white matter: an in silico, in vitro, and ex vivo study, *American journal of physiology. Heart and circulatory physiology*, 310 (2016) H1702-1714.

[45] E. Fahrlander, S. Schelhaas, A.H. Jacobs, K. Langer, PEGylated human serum albumin (HSA) nanoparticles: preparation, characterization and quantification of the PEGylation extent, *Nanotechnology*, 26 (2015) 145103.

[46] B. Srinivasan, A.R. Kolli, M.B. Esch, H.E. Abaci, M.L. Shuler, J.J. Hickman, TEER measurement techniques for in vitro barrier model systems, *Journal of laboratory automation*, 20 (2015) 107-126.

[47] M. Dadparvar, S. Wagner, S. Wien, J. Kufleitner, F. Worek, H. von Briesen, J. Kreuter, H16 human serum albumin nanoparticles--development and transport over an in vitro blood-brain barrier model, *Toxicol Lett*, 206 (2011) 60-66.

[48] S. Wagner, J. Kufleitner, A. Zensi, M. Dadparvar, S. Wien, J. Bungert, T. Vogel, F. Worek, J. Kreuter, H. von Briesen, Nanoparticulate transport of oximes over an in vitro blood-brain barrier model, *PLoS One*, 5 (2010) e14213.

[49] T. Engelhorn, S. Goerike, A. Doerfler, C. Okorn, M. Forsting, G. Heusch, R. Schulz, The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats, *J Cereb Blood Flow Metab*, 24 (2004) 467-474.

[50] A. Encarnacion, N. Horie, H. Keren-Gill, T.M. Bliss, G.K. Steinberg, M. Shamloo, Long-term behavioral assessment of function in an experimental model for ischemic stroke, *Journal of neuroscience methods*, 196 (2011) 247-257.

First revision

[51] J.B. Bederson, L.H. Pitts, M. Tsuji, M.C. Nishimura, R.L. Davis, H. Bartkowski, Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination, *Stroke*, 17 (1986) 472-476.